Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical Carcinoma.

Oved JH, Graul A, Burger RA, Schwartz LE, Reyes MC, Balis FM.

DNA Cell Biol. 2019 Oct;38(10):1143-1146. doi: 10.1089/dna.2019.4650. Epub 2019 Aug 29.

PMID:
31464522
2.

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.

Wade KNS, Brady MF, Thai T, Wang Y, Zheng B, Salani R, Tewari KS, Gray HJ, Bakkum-Gamez JN, Burger RA, Moore KN, Bookman MA.

Gynecol Oncol. 2019 Oct;155(1):69-74. doi: 10.1016/j.ygyno.2019.07.020. Epub 2019 Aug 10.

PMID:
31409486
3.

Low rate of intraperitoneal port placement in ovarian cancer patients, a population-based assessment.

Buckingham L, Koenig A, Ko EM, Brensinger CM, Latif N, Hummel C, Zhang X, Morgan MA, Burger RA, Giuntoli Ii RL.

Int J Gynecol Cancer. 2019 Sep;29(7):1177-1181. doi: 10.1136/ijgc-2019-000566. Epub 2019 Jul 12.

PMID:
31302627
4.

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.

Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS.

Gynecol Oncol. 2019 Aug;154(2):420-425. doi: 10.1016/j.ygyno.2019.05.013. Epub 2019 Jun 19.

PMID:
31229298
5.

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.

J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19.

PMID:
31216226
6.

Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.

Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA.

Am J Obstet Gynecol. 2019 Jun 14. pii: S0002-9378(19)30773-2. doi: 10.1016/j.ajog.2019.06.009. [Epub ahead of print]

PMID:
31207237
7.

Role of adjuvant chemotherapy in the management of stage IC ovarian granulosa cell tumors.

Nasioudis D, Ko EM, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Latif NA.

Gynecol Oncol Rep. 2019 Apr 17;28:145-148. doi: 10.1016/j.gore.2019.04.004. eCollection 2019 May.

8.

A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE.

Gynecol Oncol. 2019 Aug;154(2):294-301. doi: 10.1016/j.ygyno.2019.04.001. Epub 2019 Jun 4.

PMID:
31174889
9.

Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.

Nasioudis D, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Ko EM, Latif NA.

Gynecol Oncol. 2019 Aug;154(2):302-307. doi: 10.1016/j.ygyno.2019.05.009. Epub 2019 May 31.

PMID:
31155308
10.

HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.

Parmakhtiar B, Burger RA, Kim JH, Fruehauf JP.

Mol Cancer Res. 2019 Aug;17(8):1675-1686. doi: 10.1158/1541-7786.MCR-18-1109. Epub 2019 May 14.

PMID:
31088908
11.

Isolated distant lymph node metastases in ovarian cancer. Should a new substage be created?

Nasioudis D, Ko EM, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Latif NA.

Gynecol Oncol Rep. 2019 Mar 13;28:86-90. doi: 10.1016/j.gore.2019.03.008. eCollection 2019 May.

12.

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ.

Obstet Gynecol. 2019 Feb;133(2):245-254. doi: 10.1097/AOG.0000000000003086. Erratum in: Obstet Gynecol. 2019 Apr;133(4):830.

PMID:
30633128
13.

Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

Arend RC, Toboni MD, Montgomery AM, Burger RA, Olawaiye AB, Monk BJ, Herzog TJ.

Oncologist. 2018 Dec;23(12):1533-1545. doi: 10.1634/theoncologist.2018-0095. Epub 2018 Aug 23.

PMID:
30139839
14.

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Burger RA, Deng W, Makker V, Collins Y, Gray H, Debernardo R, Martin LP, Aghajanian C.

Gynecol Oncol. 2018 Sep;150(3):466-470. doi: 10.1016/j.ygyno.2018.06.017. Epub 2018 Jul 3.

15.

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA.

Gynecol Oncol. 2018 Jun;149(3):525-530. doi: 10.1016/j.ygyno.2018.03.043. Epub 2018 Mar 15.

PMID:
29550184
16.

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.

Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.

Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.

17.

Are patients willing to travel for better ovarian cancer care?

Shalowitz DI, Nivasch E, Burger RA, Schapira MM.

Gynecol Oncol. 2018 Jan;148(1):42-48. doi: 10.1016/j.ygyno.2017.10.018. Epub 2017 Nov 1.

PMID:
29079037
18.

Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.

Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ; NRG Oncology/Gynecologic Oncology Group.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx066.

19.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH.

Gynecol Oncol. 2017 Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12.

20.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ.

Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27.

21.

Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.

Phippen NT, Secord AA, Wolf S, Samsa G, Davidson B, Abernethy AP, Cella D, Havrilesky LJ, Burger RA, Monk BJ, Leath CA 3rd.

Gynecol Oncol. 2017 Oct;147(1):98-103. doi: 10.1016/j.ygyno.2017.07.121. Epub 2017 Jul 23.

22.

Readmission After Gynecologic Surgery: A Comparison of Procedures for Benign and Malignant Indications.

Cory L, Latif N, Brensinger C, Zhang X, Giuntoli RL 2nd, Burger RA, Morgan M, Ko E.

Obstet Gynecol. 2017 Aug;130(2):285-295. doi: 10.1097/AOG.0000000000002141.

PMID:
28697106
23.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.

Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RLM, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):711-717. doi: 10.1093/annonc/mdx011.

PMID:
28327917
24.

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.

Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA.

J Clin Oncol. 2016 Nov 10;34(32):3854-3863. doi: 10.1200/JCO.2016.68.1239.

25.

Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.

Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA.

JAMA Oncol. 2016 Nov 1;2(11):1427-1433. doi: 10.1001/jamaoncol.2016.1842.

26.

Inherited Mutations in Women With Ovarian Carcinoma.

Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ.

JAMA Oncol. 2016 Apr;2(4):482-90. doi: 10.1001/jamaoncol.2015.5495.

27.

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.

Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA.

Ann Oncol. 2016 Jan;27(1):114-21. doi: 10.1093/annonc/mdv500. Epub 2015 Oct 20.

29.

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.

Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM.

J Clin Oncol. 2015 Sep 10;33(26):2841-7. doi: 10.1200/JCO.2015.61.4776. Epub 2015 Aug 3.

30.

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.

Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA.

Gynecol Oncol. 2015 Oct;139(1):17-22. doi: 10.1016/j.ygyno.2015.07.103. Epub 2015 Jul 26.

31.
32.

A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.

Cohn DE, Barnett JC, Wenzel L, Monk BJ, Burger RA, Straughn JM Jr, Myers ER, Havrilesky LJ.

Gynecol Oncol. 2015 Feb;136(2):293-9. doi: 10.1016/j.ygyno.2014.10.020. Epub 2014 Oct 23.

33.

American Society of Clinical Oncology position statement on obesity and cancer.

Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, Fabian CJ, Gucalp A, Hershman DL, Hudson MM, Jones LW, Kakarala M, Ness KK, Merrill JK, Wollins DS, Hudis CA.

J Clin Oncol. 2014 Nov 1;32(31):3568-74. doi: 10.1200/JCO.2014.58.4680. Epub 2014 Oct 1.

34.

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX.

J Clin Oncol. 2014 Apr 20;32(12):1210-7. doi: 10.1200/JCO.2013.53.6524. Epub 2014 Mar 17.

35.

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.

Monk BJ, Pujade-Lauraine E, Burger RA.

Ann Oncol. 2013 Dec;24 Suppl 10:x53-x58. doi: 10.1093/annonc/mdt472. Review.

PMID:
24265406
36.

Ovarian cancer, version 2.2013.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M; National comprehensive cancer networks.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209.

PMID:
24142821
37.

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA.

J Clin Oncol. 2013 Dec 10;31(35):4400-6. doi: 10.1200/JCO.2013.49.7685. Epub 2013 Oct 14.

PMID:
24127448
38.

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP, Bookman MA.

Gynecol Oncol. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29.

39.

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L.

Gynecol Oncol. 2013 Mar;128(3):573-8. doi: 10.1016/j.ygyno.2012.11.038. Epub 2012 Dec 4.

40.

Ovarian cancer, version 3.2012.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49.

PMID:
23138163
41.

Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA.

Gynecol Oncol. 2012 Dec;127(3):495-501. doi: 10.1016/j.ygyno.2012.09.002. Epub 2012 Sep 19.

42.
43.

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group.

N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.

44.

Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.

Burger RA.

Ann Oncol. 2011 Dec;22 Suppl 8:viii65-viii68. doi: 10.1093/annonc/mdr529.

PMID:
22180405
45.

Advances in ovarian cancer disease control.

Burger RA.

Gynecol Oncol. 2012 Jan;124(1):5-9. doi: 10.1016/j.ygyno.2011.11.011. No abstract available.

PMID:
22153126
46.

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.

Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI.

Gynecol Oncol. 2012 Mar;124(3):563-8. doi: 10.1016/j.ygyno.2011.11.035. Epub 2011 Dec 1.

47.

Epithelial ovarian cancer.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Jan;9(1):82-113. No abstract available.

PMID:
21233246
48.

Overview of anti-angiogenic agents in development for ovarian cancer.

Burger RA.

Gynecol Oncol. 2011 Apr;121(1):230-8. doi: 10.1016/j.ygyno.2010.11.035. Epub 2011 Jan 8. Review.

PMID:
21215996
49.

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP.

Gynecol Oncol. 2010 Dec;119(3):484-90. doi: 10.1016/j.ygyno.2010.08.016. Epub 2010 Sep 25.

50.

Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.

Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA.

Gynecol Oncol. 2010 Dec;119(3):417-21. doi: 10.1016/j.ygyno.2010.08.010. Epub 2010 Sep 16.

Supplemental Content

Loading ...
Support Center